What’s the evidence with testing for fasting insulin
Reading File
Searching PubMed
fasting insulin measurement clinical utility insulin resistance
Searching the Web
fasting insulin testing clinical evidence guidelines 2024 2025
Reading Article
Searching PubMed
HOMA-IR fasting insulin insulin resistance diagnosis screening
Finding Sources
Reading File
Reading File
Reading File
Reading File
Searching PubMed
fasting insulin assay standardization reference range variability
Reading File
I now have enough comprehensive material. Here's a thorough synthesis:
Evidence for Fasting Insulin Testing
What It Measures and How It's Used
Fasting insulin is not a standalone diagnostic test - it's a surrogate marker for insulin resistance. The most clinically applied use is calculating HOMA-IR (Homeostatic Model Assessment of Insulin Resistance):
HOMA-IR = [Fasting insulin (μU/mL) × Fasting glucose (mmol/L)] / 22.5
The Tietz Textbook of Laboratory Medicine describes this plainly: "Measurement of insulin resistance in a routine clinical setting is difficult, and surrogate measures, such as fasting insulin concentration or the euglycemic insulin clamp, are used to provide an indirect assessment of insulin function." - Tietz Textbook of Laboratory Medicine, 7th Ed.
The Gold Standard Problem
The reference standard for measuring insulin resistance is the hyperinsulinemic-euglycemic clamp - a continuous IV insulin infusion with titrated glucose to maintain euglycemia. It directly measures how much glucose the body needs to prevent hypoglycemia during a fixed insulin infusion - a pure measure of insulin sensitivity. However, it is expensive, invasive, time-consuming, and reserved almost entirely for research. Fasting insulin exists as a practical but imperfect substitute.
The Core Limitations
1. No assay standardization
This is the biggest problem. Unlike HbA1c or glucose - which have international standardization programs - insulin assays across laboratories are not standardized. Different immunoassays use different antibodies and may cross-react with proinsulin to varying degrees. A 2026 cross-sectional study from Nepal (PMID 41857869) highlights that establishing reference intervals for fasting insulin requires population-specific calibration. This means a result of "12 μU/mL" from Lab A may not equal the same from Lab B.
2. No universal reference range
There is no agreed-upon normal or threshold value. Some labs use >25 μU/mL as a flag, others use >15. "Functional medicine" practitioners often cite <5-6 μU/mL as optimal, but this lacks RCT-derived evidence. The variability is real and not resolved.
3. Weak independent predictive power
Harrison's Principles of Internal Medicine (22nd Ed, 2025) states directly: "the inadequate evaluation of insulin action by measurement of fasting insulin levels or by homeostasis model assessment shows that insulin resistance contributes only partially..." to metabolic syndrome. In other words, HOMA-IR/fasting insulin capture only part of the insulin resistance picture.
4. Confounders are significant
Fasting insulin is affected by: fasting duration, body fat (particularly visceral), physical activity, medications (steroids, some antipsychotics, beta-blockers), time of day, and recent illness.
Where There IS Evidence for Its Use
| Context | Evidence Level |
|---|---|
| Research/clinical trials (as endpoint for IR) | Strong (consistent use as an outcome measure) |
| HOMA-IR for diagnosing insulin resistance in population studies | Moderate (validated against clamp studies) |
| PCOS - to assess hyperinsulinemia | Moderate (used in Endocrine Society guidelines) |
| NAFLD/MASLD severity assessment | Moderate (HOMA-IR correlates with steatosis and fibrosis stage) |
| Paediatric obesity screening | Weak/unclear - Harriet Lane Handbook explicitly notes: "some specialist clinics screen for vitamin D deficiency and insulin resistance (i.e., measure fasting insulin), but their clinical utility and cost effectiveness is unclear" |
| Metabolic syndrome risk stratification | Indirect (metabolic syndrome criteria don't include it - fasting glucose is used instead) |
| Predicting T2DM progression | Moderate - hyperinsulinemia precedes overt diabetes by up to 20 years (Tietz), but glucose-based tests are used clinically |
What Major Guidelines Say
- ADA 2025 Standards of Care: Recommends fasting glucose, HbA1c, and OGTT for diabetes/prediabetes screening. Fasting insulin is not part of the recommended diagnostic pathway.
- AACE/ACE: Uses clinical criteria and fasting glucose for metabolic syndrome - fasting insulin is not in the core diagnostic criteria.
- WHO: Metabolic syndrome criteria do not include fasting insulin.
- Endocrine Society PCOS guidelines: Do recommend evaluating insulin resistance in PCOS, but note that no single test is adequately validated; HOMA-IR is one option.
HOMA-IR Cutoffs (Research-Derived, Not Clinically Standardized)
- >2.5-3.0: Commonly cited threshold for insulin resistance in studies (varies by population and lab)
- >4.0-5.0: Often correlates with more significant metabolic dysfunction
- These cutoffs are population- and assay-dependent and not endorsed by major diagnostic bodies
Practical Bottom Line
Fasting insulin has genuine biological signal - hyperinsulinemia does precede T2DM, NAFLD, PCOS complications, and cardiovascular risk. The problem is not the biology - it is the measurement infrastructure: no standardized assay, no validated universal cutoff, no RCT showing that acting on fasting insulin results in better outcomes than acting on fasting glucose + clinical features alone.
It is most defensibly used:
- As part of HOMA-IR in research or structured clinical programs where the same lab is used consistently
- In PCOS to document hyperinsulinemia when deciding on insulin sensitizers
- In paediatric obesity specialist settings with acknowledged uncertainty
- To track treatment response within the same patient over time (same lab)
It is of limited standalone value as a population screening test or for routine primary care metabolic workup, given the lack of assay standardization and guideline endorsement.
Recent literature note: A 2024 review (PMID 39113244) argues that insulin resistance testing methods including HOMA-IR are "undervalued" and argues for greater clinical adoption, though this remains a minority view against mainstream guideline bodies that prefer glucose-centric diagnostics.
This is a shared conversation. Sign in to Orris to start your own chat.